GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ocumension Therapeutics (HKSE:01477) » Definitions » Cash Flow for Lease Financing

Ocumension Therapeutics (HKSE:01477) Cash Flow for Lease Financing : HK$-14.5 Mil (TTM As of Dec. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Ocumension Therapeutics Cash Flow for Lease Financing?

Ocumension Therapeutics's Cash Flow for Lease Financing for the six months ended in Dec. 2024 was HK$-6.6 Mil. Ocumension Therapeutics's Cash Flow for Lease Financing for the trailing twelve months (TTM) ended in Dec. 2024 was HK$-14.5 Mil.

Compared with last quarter (HK$-7.9 Mil in Jun. 2024 ), Ocumension Therapeutics's Cash Flow for Lease Financing increased in Dec. 2024 (HK$-6.6 Mil).

Ocumension Therapeutics Cash Flow for Lease Financing Historical Data

The historical data trend for Ocumension Therapeutics's Cash Flow for Lease Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ocumension Therapeutics Cash Flow for Lease Financing Chart

Ocumension Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cash Flow for Lease Financing
Get a 7-Day Free Trial -1.64 -4.67 -10.22 -13.61 -14.41

Ocumension Therapeutics Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Cash Flow for Lease Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -7.47 -6.63 -6.98 -7.91 -6.57

Ocumension Therapeutics Cash Flow for Lease Financing Calculation

Cash Flow for Lease Financing is change in cash flow resulting from increase or decrease in lease financing.


Cash Flow for Lease Financing for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-14.5 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ocumension Therapeutics Cash Flow for Lease Financing Related Terms

Thank you for viewing the detailed overview of Ocumension Therapeutics's Cash Flow for Lease Financing provided by GuruFocus.com. Please click on the following links to see related term pages.

Ocumension Therapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ocumension Therapeutics (HKSE:01477) » Definitions » Cash Flow for Lease Financing
Comparable Companies
HKSE:02256 HKSE:02315 HKSE:01672 HKSE:06955 HKSE:02616 HKSE:02142 HKSE:06660 HKSE:02157 HKSE:02105 HKSE:02480 VRTX ASX:CSL REGN XKRX:207940 ALNY XBRU:ARGX XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
5DG:Germany
Address
No. 1858 Yinzhongnan Road, Guoxiang Subdistrict, Wuzhong District, Suzhou, Jiangsu, CHN
Website
https://www.ocumension.com
Ocumension Therapeutics is an ophthalmic pharmaceutical platform company identifying, developing, and commercializing ophthalmic therapies. It provides a pharmaceutical total solution to address unmet ophthalmic medical needs in China. Its product candidates include OT-401 (YUTIQ), OT-101, OT-301 (NCX 470), OT-1001 (ZERVIATE), OT-502 (DEXYCU), OT-202, OT-503 (NCX 4251), OT-701, Ou Qin, Brimonidine tartrate eye drop, 0.5% moxifloxacin eye drop, OT-601-C, OT-302, OT-1301, T-1601, and OT-1602.
Executives
Liu Ye 2101 Beneficial owner
6 Dimensions Capital, L.p. 2101 Beneficial owner
Zhang Qiping 2201 Interest of corporation controlled by you
Su Zhou Fu Yan Chuang Ye Tou Zi Guan Li He Huo Qi Ye You Xian He Huo 2201 Interest of corporation controlled by you
6 Dimensions Capital Gp, Llc 2201 Interest of corporation controlled by you
Su Zhou Tong He Er Qi Chuang Ye Tou Zi He Huo Qi Ye You Xian He Huo 2101 Beneficial owner
Su Zhou Yun Zhang Tou Zi Zi Xun You Xian Gong Si 2201 Interest of corporation controlled by you
Boyu Capital Fund Iv, L.p. 2201 Interest of corporation controlled by you
Boyu Capital Group Holdings Ltd 2201 Interest of corporation controlled by you
Boyu Capital General Partner Iv, Ltd 2201 Interest of corporation controlled by you
Summer Iris Limited 2101 Beneficial owner
Alcon Pharmaceuticals Ltd 2101 Beneficial owner
Alcon Inc. 2201 Interest of corporation controlled by you
Temasek Holdings (private) Limited 2201 Interest of corporation controlled by you
The Capital Group Companies, Inc. 2201 Interest of corporation controlled by you

Ocumension Therapeutics Headlines

No Headlines